• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于肿瘤形态学特征对高级别浆液性卵巢癌的分类。

Classification of High-Grade Serous Ovarian Cancer Using Tumor Morphologic Characteristics.

机构信息

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston.

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Morsani College of Medicine, University of South Florida, Tampa.

出版信息

JAMA Netw Open. 2022 Oct 3;5(10):e2236626. doi: 10.1001/jamanetworkopen.2022.36626.

DOI:10.1001/jamanetworkopen.2022.36626
PMID:36239936
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9568802/
Abstract

IMPORTANCE

Despite similar histologic appearance among high-grade serous ovarian cancers (HGSOCs), clinical observations suggest vast differences in gross appearance. There is currently no systematic framework by which to classify HGSOCs according to their gross morphologic characteristics.

OBJECTIVE

To develop and characterize a gross morphologic classification system for HGSOC.

DESIGN, SETTING, AND PARTICIPANTS: This cohort study included patients with suspected advanced-stage ovarian cancer who presented between April 1, 2013, and August 5, 2016, to the University of Texas MD Anderson Cancer Center, a large referral center. Patients underwent laparoscopic assessment of disease burden before treatment and received a histopathologic diagnosis of HGSOC. Researchers assigning morphologic subtype and performing molecular analyses were blinded to clinical outcomes. Data analysis was performed between April 2020 and November 2021.

EXPOSURES

Gross tumor morphologic characteristics.

MAIN OUTCOMES AND MEASURES

Clinical outcomes and multiomic profiles of representative tumor samples of type I or type II morphologic subtypes were compared.

RESULTS

Of 112 women (mean [SD] age 62.7 [9.7] years) included in the study, most patients (84% [94]) exhibited a predominant morphologic subtype and many (63% [71]) had a uniform morphologic subtype at all involved sites. Compared with those with uniform type I morphologic subtype, patients with uniform type II morphologic subtype were more likely to have a favorable Fagotti score (83% [19 of 23] vs 46% [22 of 48]; P = .004) and thus to be triaged to primary tumor reductive surgery. Similarly, patients with uniform type II morphologic subtype also had significantly higher mean (SD) estimated blood loss (639 [559; 95% CI, 391-887] mL vs 415 [527; 95% CI, 253-577] mL; P = .006) and longer mean (SD) operative time (408 [130; 95% CI, 350-466] minutes vs 333 [113; 95% CI, 298-367] minutes; P = .03) during tumor reductive surgery. Type I tumors had enrichment of epithelial-mesenchymal transition (false discovery rate [FDR] q-value, 3.10 × 10-24), hypoxia (FDR q-value, 1.52 × 10-5), and angiogenesis pathways (FDR q-value, 2.11 × 10-2), whereas type II tumors had enrichment of pathways related to MYC signaling (FDR q-value, 2.04 × 10-9) and cell cycle progression (FDR q-value, 1.10 × 10-5) by integrated proteomic and transcriptomic analysis. Abundances of metabolites and lipids also differed between the 2 morphologic subtypes.

CONCLUSIONS AND RELEVANCE

This study identified 2 novel, gross morphologic subtypes of HGSOC, each with unique clinical features and molecular signatures. The findings may have implications for triaging patients to surgery or chemotherapy, identifying outcomes, and developing tailored therapeutic strategies.

摘要

重要性

尽管高级别浆液性卵巢癌 (HGSOC) 的组织学表现相似,但临床观察表明其大体外观存在巨大差异。目前尚无系统的框架可根据其大体形态特征对 HGSOC 进行分类。

目的

制定和描述 HGSOC 的大体形态分类系统。

设计、地点和参与者:这项队列研究纳入了 2013 年 4 月 1 日至 2016 年 8 月 5 日期间在德克萨斯大学 MD 安德森癌症中心就诊的疑似晚期卵巢癌患者,该中心是一家大型转诊中心。患者在治疗前接受腹腔镜评估疾病负担,并接受 HGSOC 的组织病理学诊断。进行形态亚型分配和进行分子分析的研究人员对临床结果不知情。数据分析于 2020 年 4 月至 2021 年 11 月进行。

暴露

肿瘤大体形态特征。

主要结果和测量指标

比较了 I 型或 II 型形态亚型的代表性肿瘤样本的临床结果和多组学特征。

结果

在纳入研究的 112 名女性患者(平均 [标准差] 年龄 62.7 [9.7] 岁)中,大多数患者(84%[94%])表现出主要的形态亚型,许多患者(63%[71%])在所有受累部位均具有一致的形态亚型。与具有一致的 I 型形态亚型的患者相比,具有一致的 II 型形态亚型的患者更有可能具有良好的 Fagotti 评分(83%[19/23] vs 46%[22/48];P = .004),因此更有可能接受原发性肿瘤减瘤手术。同样,具有一致的 II 型形态亚型的患者在肿瘤减瘤手术中也具有显著更高的平均(标准差)估计失血量(639[559;95%CI,391-887]mL 与 415[527;95%CI,253-577]mL;P = .006)和更长的平均(标准差)手术时间(408[130;95%CI,350-466]min 与 333[113;95%CI,298-367]min;P = .03)。I 型肿瘤在上皮-间充质转化(错误发现率 [FDR] q 值,3.10×10-24)、缺氧(FDR q 值,1.52×10-5)和血管生成途径(FDR q 值,2.11×10-2)中富集,而 II 型肿瘤在 MYC 信号通路(FDR q 值,2.04×10-9)和细胞周期进展(FDR q 值,1.10×10-5)中富集,这是通过整合蛋白质组学和转录组学分析得出的。这两种形态亚型之间的代谢物和脂质丰度也存在差异。

结论和相关性

这项研究确定了 2 种新型的 HGSOC 大体形态亚型,每种亚型都具有独特的临床特征和分子特征。这些发现可能对患者手术或化疗的分诊、识别结果以及制定针对性的治疗策略具有重要意义。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35c0/9568802/4953bf34d63c/jamanetwopen-e2236626-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35c0/9568802/ecec98ec4543/jamanetwopen-e2236626-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35c0/9568802/7bd84138f648/jamanetwopen-e2236626-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35c0/9568802/4953bf34d63c/jamanetwopen-e2236626-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35c0/9568802/ecec98ec4543/jamanetwopen-e2236626-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35c0/9568802/7bd84138f648/jamanetwopen-e2236626-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35c0/9568802/4953bf34d63c/jamanetwopen-e2236626-g003.jpg

相似文献

1
Classification of High-Grade Serous Ovarian Cancer Using Tumor Morphologic Characteristics.基于肿瘤形态学特征对高级别浆液性卵巢癌的分类。
JAMA Netw Open. 2022 Oct 3;5(10):e2236626. doi: 10.1001/jamanetworkopen.2022.36626.
2
Characterizing morphologic subtypes of high-grade serous ovarian cancer by CT: a retrospective cohort study.通过 CT 对高级别浆液性卵巢癌的形态学亚型进行特征分析:一项回顾性队列研究。
Int J Gynecol Cancer. 2023 Jun 5;33(6):937-943. doi: 10.1136/ijgc-2022-004206.
3
Pooled Clustering of High-Grade Serous Ovarian Cancer Gene Expression Leads to Novel Consensus Subtypes Associated with Survival and Surgical Outcomes.高级别浆液性卵巢癌基因表达的合并聚类导致与生存和手术结果相关的新型共识亚型。
Clin Cancer Res. 2017 Aug 1;23(15):4077-4085. doi: 10.1158/1078-0432.CCR-17-0246. Epub 2017 Mar 9.
4
Morphologic and molecular correlates of EZH2 as a predictor of platinum resistance in high-grade ovarian serous carcinoma.EZH2 的形态学和分子相关性可作为预测高级别卵巢浆液性癌铂类耐药的指标。
BMC Cancer. 2021 Jun 17;21(1):714. doi: 10.1186/s12885-021-08413-3.
5
Evolving population-based statistics for rare epithelial ovarian cancers.不断变化的基于人群的罕见上皮性卵巢癌统计数据。
Gynecol Oncol. 2020 Apr;157(1):3-11. doi: 10.1016/j.ygyno.2019.11.122. Epub 2020 Jan 15.
6
Prognosis comparison between small cell carcinoma of ovary and high-grade serous ovarian cancer: A retrospective observational cohort study.卵巢小细胞癌与高级别浆液性卵巢癌的预后比较:一项回顾性观察性队列研究。
Front Endocrinol (Lausanne). 2023 Jan 18;14:1103429. doi: 10.3389/fendo.2023.1103429. eCollection 2023.
7
BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.高级别浆液性晚期卵巢癌的BRCA突变状态、初始疾病表现及临床结局:一项多中心研究
Am J Obstet Gynecol. 2017 Sep;217(3):334.e1-334.e9. doi: 10.1016/j.ajog.2017.05.036. Epub 2017 May 23.
8
Association between morphologic CT imaging traits and prognostically relevant gene signatures in women with high-grade serous ovarian cancer: a hypothesis-generating study.高级别浆液性卵巢癌女性患者的CT形态学影像特征与预后相关基因特征之间的关联:一项假设生成研究。
Radiology. 2015 Mar;274(3):742-51. doi: 10.1148/radiol.14141477. Epub 2014 Nov 10.
9
Cancer-associated stroma significantly contributes to the mesenchymal subtype signature of serous ovarian cancer.癌相关基质显著促进浆液性卵巢癌的间充质亚型特征。
Gynecol Oncol. 2019 Feb;152(2):368-374. doi: 10.1016/j.ygyno.2018.11.014. Epub 2018 Nov 15.
10
Better or worse? The prognostic role of the mesenchymal subtype in patients with high-grade serous ovarian carcinoma: A systematic review and meta-analysis.更好还是更差?间充质亚型在高级别浆液性卵巢癌患者中的预后作用:系统评价和荟萃分析。
Cancer Med. 2022 Oct;11(20):3761-3770. doi: 10.1002/cam4.4752. Epub 2022 Apr 17.

引用本文的文献

1
A pioneering artificial intelligence tool to predict treatment outcomes in ovarian cancer via diagnostic laparoscopy.一种通过诊断性腹腔镜检查预测卵巢癌治疗结果的开创性人工智能工具。
Sci Rep. 2025 Apr 25;15(1):14437. doi: 10.1038/s41598-025-98434-w.
2
The silent spread: exploring diverse metastatic pathways in high-grade serous ovarian cancer.沉默的扩散:探索高级别浆液性卵巢癌的多种转移途径
Front Med (Lausanne). 2025 Mar 5;12:1539024. doi: 10.3389/fmed.2025.1539024. eCollection 2025.
3
Complement activation at the interface between adipocytes and cancer cells drives tumor progression.

本文引用的文献

1
Hypoxia-Mediated Decrease of Ovarian Cancer Cells Reaction to Treatment: Significance for Chemo- and Immunotherapies.缺氧介导的卵巢癌细胞对治疗反应的降低:对化疗和免疫治疗的意义。
Int J Mol Sci. 2020 Dec 14;21(24):9492. doi: 10.3390/ijms21249492.
2
Evaluating genomic biomarkers associated with resistance or sensitivity to chemotherapy in patients with advanced breast and colorectal cancer.评估晚期乳腺癌和结直肠癌患者中与化疗耐药或化疗敏感性相关的基因组生物标志物。
J Oncol Pharm Pract. 2021 Sep;27(6):1371-1381. doi: 10.1177/1078155220951845. Epub 2020 Aug 26.
3
Beyond thrombosis: the impact of tissue factor signaling in cancer.
脂肪细胞与癌细胞界面处的补体激活驱动肿瘤进展。
JCI Insight. 2025 Feb 18;10(6):e184935. doi: 10.1172/jci.insight.184935.
4
Successful laparoscopic cytoreductive surgery for multiple (three) advanced recurrences of AGCT in a young woman. A case report.一名年轻女性多次(三次)晚期复发性无性细胞瘤的成功腹腔镜细胞减灭术。病例报告。
Int J Surg Case Rep. 2025 Feb;127:110960. doi: 10.1016/j.ijscr.2025.110960. Epub 2025 Jan 27.
5
Deguelin Restores Paclitaxel Sensitivity in Paclitaxel-Resistant Ovarian Cancer Cells via Inhibition of the EGFR Signaling Pathway.鱼藤素通过抑制表皮生长因子受体(EGFR)信号通路恢复耐紫杉醇卵巢癌细胞对紫杉醇的敏感性。
Cancer Manag Res. 2024 May 28;16:507-525. doi: 10.2147/CMAR.S457221. eCollection 2024.
6
A Workflow for Meaningful Interpretation of Classification Results from Handheld Ambient Mass Spectrometry Analysis Probes.手持式环境质谱分析探头分类结果的有意义解释工作流程。
Int J Mol Sci. 2024 Mar 20;25(6):3491. doi: 10.3390/ijms25063491.
7
Overview of Tumor Heterogeneity in High-Grade Serous Ovarian Cancers.高级别浆液性卵巢癌中的肿瘤异质性概述。
Int J Mol Sci. 2023 Oct 11;24(20):15077. doi: 10.3390/ijms242015077.
8
Diagnostics and treatment of ovarian cancer in the era of precision medicine - opportunities and challenges.精准医学时代卵巢癌的诊断与治疗——机遇与挑战
Front Oncol. 2023 Sep 6;13:1227657. doi: 10.3389/fonc.2023.1227657. eCollection 2023.
9
Overall survival prediction models for gynecological endometrioid adenocarcinoma with squamous differentiation (GE-ASqD) using machine-learning algorithms.使用机器学习算法预测妇科子宫内膜样腺癌伴鳞状分化(GE-ASqD)的总生存模型。
Sci Rep. 2023 May 24;13(1):8395. doi: 10.1038/s41598-023-33748-1.
10
Integrating single-cell RNA sequencing and prognostic model revealed the carcinogenicity and clinical significance of FAM83D in ovarian cancer.整合单细胞RNA测序和预后模型揭示了FAM83D在卵巢癌中的致癌性及临床意义。
Front Oncol. 2022 Dec 8;12:1055648. doi: 10.3389/fonc.2022.1055648. eCollection 2022.
超越血栓形成:组织因子信号在癌症中的影响。
J Hematol Oncol. 2020 Jul 14;13(1):93. doi: 10.1186/s13045-020-00932-z.
4
Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer.高级别浆液性卵巢癌临床定义亚组的分子分析。
Cell Rep. 2020 Apr 14;31(2):107502. doi: 10.1016/j.celrep.2020.03.066.
5
Resistance Mechanisms to Anti-angiogenic Therapies in Cancer.癌症中抗血管生成疗法的耐药机制
Front Oncol. 2020 Feb 27;10:221. doi: 10.3389/fonc.2020.00221. eCollection 2020.
6
Interference with SMO increases chemotherapy drug sensitivity of A2780/DDP cells by inhibiting the Hh/Gli signaling pathway.干扰 SMO 可通过抑制 Hh/Gli 信号通路增加 A2780/DDP 细胞对化疗药物的敏感性。
J Cell Biochem. 2020 Jun;121(5-6):3256-3265. doi: 10.1002/jcb.29593. Epub 2020 Jan 6.
7
PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside.PI3K/Akt/mTOR 抑制剂在癌症中的应用:从实验室到临床。
Semin Cancer Biol. 2019 Dec;59:125-132. doi: 10.1016/j.semcancer.2019.07.009. Epub 2019 Jul 16.
8
Aberrant Activation Of Hedgehog Signalling Promotes Cell Migration And Invasion Via Matrix Metalloproteinase-7 In Ovarian Cancer Cells.刺猬信号通路的异常激活通过基质金属蛋白酶-7促进卵巢癌细胞的迁移和侵袭。
J Cancer. 2019 Jan 29;10(4):990-1003. doi: 10.7150/jca.26478. eCollection 2019.
9
New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer.上皮-间质转化的机制新见解及其对癌症的影响。
Nat Rev Mol Cell Biol. 2019 Feb;20(2):69-84. doi: 10.1038/s41580-018-0080-4.
10
Laparoscopic Surgical Algorithm to Triage the Timing of Tumor Reductive Surgery in Advanced Ovarian Cancer.腹腔镜手术算法在晚期卵巢癌中对肿瘤减瘤手术时机进行分类。
Obstet Gynecol. 2018 Sep;132(3):545-554. doi: 10.1097/AOG.0000000000002796.